Leukemia xenograft regression and survival after treatment with anti-CD45 PRIT using 213Bi-DOTA-biotin. Athymic mice bearing HEL xenografts were injected intravenously via tail vein 2 days after tumor implantation with 1.4 nmol of anti-CD45 Ab-SA conjugate followed 22 hours later with 5.8 nmol of CA and subsequently with 1.2 nmol of 213Bi-DOTA-biotin (400 μCi and 800 μCi) 3 hours later. Tumor-bearing control mice were either untreated or treated with a nonbinding control Ab-SA conjugate before 800 μCi radiolabeled DOTA-biotin injection. (A) Tumor volume curves are truncated at the time of death because of excessive tumor growth in the first mouse in each group. (B) Mice were analyzed for survival as a function of time. †Deaths resulting from toxicity.
